Compare McKesson Corporation (MCK) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Xylem, Inc. — how do they compare? McKesson Corporation trades at $832.45 (market cap $97.35B), while Xylem, Inc. trades at $117 (market cap $28.67B). The key difference: McKesson Corporation is far larger — about 3.4× Xylem, Inc.'s market cap, and Xylem, Inc. pays the higher dividend (1.43%). Which is the better fit depends on your goals.
| MCK | XYL | |
|---|---|---|
Market Cap | $97.35B | $28.67B |
Sector | Health | Industrials |
52-Week High | $995.69 | $152.95 |
52-Week Low | $659.01 | $106.34 |
Enterprise Value | $101.98B | $29.92B |
Dividend Yield | 0.39% | 1.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $828.84, down 1.49% on the day, with a bullish technical outlook supported by moving averages and key support at $826. The company shows strong revenue growth, reaching $359.05B in 2025, and has beaten EPS estimates for three consecutive quarters. Analyst sentiment is overwhelmingly positive with 24 buy ratings and a consensus price target of $932.83, indicating 12.5% upside potential.
The outlook for MCK remains favorable due to consistent earnings beats, robust cash flow generation, and leadership in healthcare distribution. Risks include thin profit margins (1.18% net margin) and high liabilities relative to equity. Investors should focus on execution in specialty pharma and oncology services as key growth drivers amid competitive and regulatory pressures.
XYL trades at $117.00, down 4.71% today, amid mixed technical signals with a bullish overall trend but neutral oscillators. Fundamentally, the company shows steady revenue growth from $8.6B in 2024 to $9.04B in 2025, with net income margins improving to 10.79%. Recent earnings beats and a consistent dividend history support investor confidence, while analyst consensus leans slightly bullish with a $152.71 price target.
The outlook for XYL remains positive given its earnings momentum and strategic partnerships in water technology. Key risks include execution challenges in integrating new leadership and macroeconomic pressures on industrial spending. The stock offers potential upside to analyst targets but requires monitoring of upcoming Q2 2026 results due July 28, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
